IMP-9064 is under clinical development by IMPACT Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMP-9064’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMP-9064 is under development for the treatment of ATM mutated solid tumors, endometrial cancer, metastatic colorectal cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer. The therapeutic candidate acts by targeting ataxia telangiectasia and rad3 related protein (ATR) kinase. It is administered through oral route.
IMPACT Therapeutics overview
IMPACT Therapeutics (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; and IMP04297 is an efficacious in several animal cancer models. The company also develops IMP3138, a small molecular microtubule inhibitor clinical candidate with advantages in vitro and in vivo over paclitaxel. It also operates oncology drug discovery and several anticancer drug development projects. IMPACT is headquartered in Nanjing, China.
For a complete picture of IMP-9064’s drug-specific PTSR and LoA scores, buy the report here.